Home  /  Resource Library  /  Patient-reported time toxicity with bispecific antibody therapies in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma

Patient-reported time toxicity with bispecific antibody therapies in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma

Study investigated patient reported outcomes and preferences with bispecifics in DLBCL and follicular lymphoma.